TABLE 2.
Overview of classes and indications of combinations
| Indications a type of combination | All indications n = 104 a | Active IBD (A) n = 70 | Both active IBD and active IMID/EIM (B) n = 10 | Active IMID/EIM (C) n = 23 |
|---|---|---|---|---|
| Anti‐TNF + VZ | 41 | 31 | 5 | 5 |
| Anti‐TNF + anti‐IL | 11 | 7 | 1 | 3 |
| Anti‐IL + VZ | 21 | 16 | – | 5 |
| Tofacitinib + anti‐TNF | 1 | 1 | – | – |
| Tofacitinib + VZ | 13 | 10 | 2 | 1 |
| Anti‐IL + anti‐IL | 1 | 1 | ‐ | ‐ |
| Combinations with other molecules b | 16 a | 4 | 2 | 9 |
Abbreviations: EIM, extra‐intestinal manifestation; IBD, Inflammatory bowel disease; IL, Interleukin; IMID, immune mediated inflammatory disease; TNF, Tumour Necrosis Factor; VZ, vedolizumab.
a
One combination was Risankizumab + Tacrolimus for IBD and liver transplantation.
b
Apremilast, Ciclosporine, Rituximab, Leflunomide and Tacrolimus. Details of all the combinations is given in Supplementary Table S2.